Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy

Frontiers in Cardiovascular Medicine

Y. M. C. Henskens¹  R. G. van Oerle¹  P. E. J. van der Meijden¹  S. Zwaveling²  L. Veenstra³  A. W. J. van't Hof⁴  M. J. A. Vries⁵  H. ten Cate⁶  R. H. Olie⁶  C. P. D. M. de Breet⁷ 

[1] Department of Biochemistry–CARIM, Maastricht University, Maastricht, Netherlands;Department of Biochemistry–CARIM, Maastricht University, Maastricht, Netherlands;Groene Hart Ziekenhuis, Gouda, Netherlands;Department of Cardiology, Zuyderland Medisch Centrum, Heerlen, Netherlands;Department of Cardiology, Zuyderland Medisch Centrum, Heerlen, Netherlands;Department of Cardiology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands;Department of Internal Medicine, Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Netherlands;Department of Internal Medicine, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands;Department of Biochemistry–CARIM, Maastricht University, Maastricht, Netherlands;Department of Internal Medicine, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands;Department of Internal Medicine, Zuyderland Medisch Centrum, Heerlen, Netherlands;

关键词: thrombin generation;    dual antiplatelet therapy;    bleeding risk;    percutaneous coronary intervention;    coagulation factors;   

DOI  :  10.3389/fcvm.2021.679934

来源: Frontiers

【 授权许可】

CC BY